Differences between long-acting insulins for the treatment of type 2 diabetes (Q37773993)

23 August 2017

1 reference

title

Differences between long-acting insulins for the treatment of type 2 diabetes (English)

1 reference

23 August 2017

0 references

Michael Gejl Jensen

1

1 reference

23 August 2017

Mikkel Hansen

series ordinal

2

1 reference

23 August 2017

Birgitte Brock

series ordinal

3

1 reference

23 August 2017

Jørgen Rungby

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

12

1 reference

23 August 2017

2027-2035

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Intensive versus conventional glucose control in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

New strategies in insulin treatment: analogues and noninvasive routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

An update on the long-acting insulin analogue glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Medication taking and diabetes: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Reproducibility and variability in the action of injected insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494831

10.1517/14656566.2010.494831

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference